What is the most recent earnings date for GALT stock?
GALECTIN THERAPEUTICS INC (GALT) last reported earnings on 11/14/2025.
NASDAQ:GALT • US3632252025
Past quarterly earnings results for GALECTIN THERAPEUTICS INC (GALT), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.13 | -0.11 | -15.86% | 27.78% | - | - | ||
| Q2 2025 | -0.12 | -0.16 | 26.47% | 40.00% | - | - | ||
| Q1 2025 | -0.15 | -0.20 | 26.47% | 21.05% | - | - | ||
| Q4 2024 | -0.19 | -0.16 | -16.42% | -18.75% | - | - | ||
| Q3 2024 | -0.18 | -0.20 | 11.76% | 25.00% | - | - | ||
| Q2 2024 | -0.20 | -0.16 | -22.55% | -33.33% | - | - | ||
| Q1 2024 | -0.19 | -0.16 | -16.42% | - | - | - | ||
| Q4 2023 | -0.16 | -0.16 | 1.96% | 11.11% | - | - | ||
| Q3 2023 | -0.24 | -0.16 | -47.06% | -71.43% | - | - | ||
| Q2 2023 | -0.15 | -0.21 | 29.97% | 6.25% | - | - | ||
| Q1 2023 | -0.19 | -0.21 | 11.30% | -11.76% | - | - | ||
| Q4 2022 | -0.18 | -0.17 | -3.81% | -50.00% | - | - | ||
| Q3 2022 | -0.14 | -0.20 | 31.37% | - | - | - | ||
| Q2 2022 | -0.16 | -0.19 | 17.44% | -14.29% | - | - | ||
| Q1 2022 | -0.17 | -0.14 | -19.05% | -54.55% | - | - | ||
| Q4 2021 | -0.12 | -0.19 | 38.08% | 7.69% | - | - | ||
| Q3 2021 | -0.14 | -0.18 | 23.75% | -40.00% | - | - | ||
| Q2 2021 | -0.14 | -0.18 | 23.75% | -27.27% | - | - | ||
| Q1 2021 | -0.11 | -0.17 | 36.56% | -83.33% | - | - | ||
| Q4 2020 | -0.13 | -0.16 | 20.34% | - | - | - | ||
| Q3 2020 | -0.10 | -0.14 | 29.97% | - | - | - | ||
| Q2 2020 | -0.11 | -0.10 | -13.52% | - | - | - | ||
| Q1 2020 | -0.06 | -0.09 | 34.64% | - | - | - |
Notes
GALECTIN THERAPEUTICS INC (GALT) last reported earnings on 11/14/2025.
GALECTIN THERAPEUTICS INC (GALT) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, GALECTIN THERAPEUTICS INC (GALT) has beaten EPS estimates in 2 out of 4 releases.